pharmaphorum
SEPTEMBER 2, 2020
The UK’s medicines regulator has published long-awaited guidance on regulation of medicines and medical devices as the UK approaches the end of its Brexit transition period at the end of the year. This would see the UK mirroring decisions made by the European Medicines Agency, while also laying out a process should companies wish to file for a separate approval in the UK.
Pharma Times
SEPTEMBER 1, 2020
Clinical development of AZD1222 is progressing globally with late-stage clinical trials ongoing in the UK, Brazil and South Africa
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
SEPTEMBER 2, 2020
A study of their therapy and clinical trials of other experimental treatments are offering glimmers of hope that paralysis from the disorder can be slowed.
Outsourcing Pharma
SEPTEMBER 3, 2020
Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
SEPTEMBER 2, 2020
Digital health firm Mobio Interactive has closed a $1.8 million seed fund to advance development of its meditation app Am Mindfulness. Mobio said that the app, known as Am for short, is the first and only meditation app to outperform placebo in randomised controlled trials. MI’s Seed raise was led by the Singapore-based Verge HealthTech Fund along with Atlas Asset Management , Creative Ventures and VC giant SOSV.
Pharma Times
SEPTEMBER 3, 2020
Scientists have discovered that hard-to-treat pancreatic cancer hijacks a key immune system response
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Outsourcing Pharma
AUGUST 31, 2020
A recent study from healthcare insights company Sermo shares information and perspectives that trial and pharma professionals could learn from.
pharmaphorum
SEPTEMBER 2, 2020
While the effects of COVID-19 have been devastating for many industries, its positive impact on accelerating the uptake of digital health technologies and virtual collaboration solutions is undeniable. This has been a long time coming and there are countless reasons why I believe virtual collaboration and medical education are here to stay, long after there is a vaccine for COVID-19 and physical distancing guidelines have been lifted. 1.
Pharma Times
SEPTEMBER 3, 2020
NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources
Eye on FDA
SEPTEMBER 2, 2020
Since last week’s posting regarding FDA credibility being on the line, there has been a swirl of activity and commentary around the evaluation of vaccine research for COVID-19 that would seem to have exacerbated the problem. For context, last week the President issued a tweet stating that people were operating within FDA to slow progress on a vaccine without supplying any evidence, credible or otherwise, to support that.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
SEPTEMBER 1, 2020
A new scientific report offers a comprehensive review of protein targets, associated COVID-19 drug candidates to date and other revealing information.
pharmaphorum
SEPTEMBER 1, 2020
Sanofi has drawn another blank in its attempt to repurpose its IL-6 drug Kevzara to tackle the extreme immune reaction seen in serious cases of COVID-19. The French pharma and development partner Regeneron have been testing Kevzara (sarilumab) in patients severely or critically ill and hospitalised with COVID-19. In severe cases of COVID-19, patients suffer a “cytokine storm” where the immune system becomes overstimulated and attacks the body.
Pharma Times
SEPTEMBER 1, 2020
Rybelsus is the world’s first and only oral GLP-1 receptor agonist
NY Times
SEPTEMBER 1, 2020
Meditation apps, tinctures, stress-busting gummies — spending on commercials for all of them is rising amid the pandemic’s climbing death toll and economic strain.
Outsourcing Pharma
SEPTEMBER 3, 2020
A company leader outlines the importance of increasing diversity in clinical trial patient populations, and how researchers can improve their results.
pharmaphorum
SEPTEMBER 2, 2020
Cancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to respond. But many patients still do not respond to therapies such as Merck & Co’s anti PD-1 therapy Keytruda (pembrolizumab), or go on to develop progressive disease, and pharma companies are looking for new second-line therapies.
Pharma Times
SEPTEMBER 2, 2020
The decision allows use of the therapy in the EU in children as young as six years of age
NY Times
SEPTEMBER 3, 2020
Pfizer’s chief executive, Dr. Albert Bourla, said the drug-making company is in a “very advanced stage” and should know by the end of October whether the coronavirus vaccine they are developing is safe and effective.
Drug Channels
SEPTEMBER 4, 2020
This week, I’m rerunning some popular posts while I work on the forthcoming 2020-21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post and comments from June 2020. It was one of my most popular articles in 2020. One minor update: PrudentRx finally has a website! It's still uninformative and misleading, but I suspect that my original article shamed them into putting up a better placeholder.
pharmaphorum
SEPTEMBER 3, 2020
GlaxoSmithKline is opening a £10 million artificial intelligence (AI) research hub in King’s Cross, London, according to a press report. The area is being reimagined as a life sciences and technology hub and is already home to the Francis Crick Institute biomedical research organisation. King’s Cross is also home to Google’s DeepMind artificial intelligence company, which has already been involved in life sciences projects such as using the technology to predict acute kidney injury.
Pharma Times
SEPTEMBER 1, 2020
Sanofi and Regeneron do not anticipate carrying out further research on Kevzara in COVID-19
Pharma Mirror
SEPTEMBER 2, 2020
Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the Group”; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong, announced the signing of a letter of intent (“Letter of Intent”) with Fosun Industrial Co.
Drug Channels
SEPTEMBER 3, 2020
This week, I’m rerunning some popular posts while I work on the forthcoming 2020-21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post and comments from June 2020. I'll have an update on accumulators in September. COVID-19 has not stopped the wheels of policy bureaucracy from grinding. Last week, the Centers for Medicare and Medicaid Services (CMS) released its final Notice of Benefit and Payment Parameters for the 2021 benefit year.
pharmaphorum
SEPTEMBER 4, 2020
Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. The French pharma in April joined forces with the UK’s GSK to produce the vaccine, with Sanofi contributing an antigen that produces the immune reaction. Meanwhile GSK is producing the booster that reduces the amount of active ingredient necessary to produce an effect.
Pharma Times
SEPTEMBER 4, 2020
Four papers have been published reinforcing evidence that steroids can significantly improve the outcomes for those critically ill with the virus
Drug Patent Watch
SEPTEMBER 2, 2020
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A. van Bodegraven, Nanne K.H. de Boer, and Chris J.J. Mulder in Drug Discovery Today under a Creative Commons…. The post Finding hidden treasures in old drugs: the challenges and importance of licensing generics appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
SEPTEMBER 2, 2020
This week, I’m rerunning some popular posts while I work on the forthcoming 2020-21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post and comments from July 2020. I'm rerunning this post to provide context for manufacturers' recent actions regarding 340B contract pharmacies. The "SUBREGULATORY MISCHIEF" section below explains crucial background.
pharmaphorum
SEPTEMBER 4, 2020
England is to trial population testing for COVID-19 in places such as schools, colleges and busy public spaces. Health secretary Matt Hancock said the government has earmarked an extra £500 million ($552 million) to scale up testing and capacity to launch community pilots as fears mount about as second wave of infections during the winter months. The population testing will be made possible by new test kits capable of giving results within 15 minutes or so.
Pharma Times
SEPTEMBER 2, 2020
Over 400 participants are being enrolled in the Phase I/II study after promising preclinical safety and immunogenicity data
Pharma Marketing Network
SEPTEMBER 1, 2020
Despite the COVID-19 pandemic, digital display advertising will continue to grow this year with more investments in video ads. According to eMarketer, U.S. advertisers will increase investments in video by 11.3% this year to $35.45 billion, making it the only digital ad format to grow at a double-digit rate this year. For the first time ever, video will account for more than a quarter of all U.S. digital ad spending.
Drug Channels
AUGUST 31, 2020
On Friday, GoodRx filed its Form S-1 in preparation for going public. Link below. The company is insanely profitable. Its adjusted net income—earnings before interest, taxes, depreciation, and amortization (EBITDA)—is an astonishing 40%. Below, I provide my overview of how our crazy drug channel system enables GoodRx’s good fortune. You will admire the GoodRx management team’s business savvy in building a company that lowers out-of-pocket costs for consumers.
pharmaphorum
SEPTEMBER 2, 2020
Bilal Babar from THE PLANNING SHOP tells us how the movement of birds and Swarm Technology have helped develop multiple market research tools. Flocks of birds wheeling, swooping and gliding in unison, as if choreographed, are a wonderful sight. The benefit to members of the flock are many including safety from predators, more eyes to spot food and natural selection – those that can’t keep up or fly in a very densely populated flock and make such sharp turns without colliding don’t survive.
Pharma Times
SEPTEMBER 2, 2020
The test can typically identify SARS-CoV-2 infection within 15 minutes
Outsourcing Pharma
SEPTEMBER 3, 2020
The companies will join forces to use IntelGenxâs polymeric film technologies for development of pharmaceutical-grade psychedelic drug treatments.
NY Times
SEPTEMBER 2, 2020
The idea behind convalescent plasma is attractively simple, but we just don’t know enough.
Expert insights. Personalized for you.
123 
Let's personalize your content